| pubmed-article:6162997 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6162997 | lifeskim:mentions | umls-concept:C0025344 | lld:lifeskim |
| pubmed-article:6162997 | lifeskim:mentions | umls-concept:C0027051 | lld:lifeskim |
| pubmed-article:6162997 | lifeskim:mentions | umls-concept:C0019134 | lld:lifeskim |
| pubmed-article:6162997 | lifeskim:mentions | umls-concept:C0205178 | lld:lifeskim |
| pubmed-article:6162997 | lifeskim:mentions | umls-concept:C2347804 | lld:lifeskim |
| pubmed-article:6162997 | lifeskim:mentions | umls-concept:C1561960 | lld:lifeskim |
| pubmed-article:6162997 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
| pubmed-article:6162997 | lifeskim:mentions | umls-concept:C1948053 | lld:lifeskim |
| pubmed-article:6162997 | lifeskim:mentions | umls-concept:C0699435 | lld:lifeskim |
| pubmed-article:6162997 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:6162997 | pubmed:dateCreated | 1981-5-26 | lld:pubmed |
| pubmed-article:6162997 | pubmed:abstractText | The use of the methods of multiple (35) precordial ECG leads and serial tests for the activity of creatine phosphokinase and its MB fraction allows quantitative assessment of the dimensions of the necrotic zones. In injection of contrykal with heparin the dimensions of the myocardial infarct decreased. In early injection of these agents, the clinical and electrocardiographic findings improved more rapidly and the infarction zone was smaller. Injection of contrykal with heparin arrested the anginose attack more rapidly, corrected the peripheral symptoms of circulatory insufficiency, normalized arterial pressure and relieved the congestive phenomena in the lungs within a shorter period of time. The combined use of these agents is a pathogenetically substantiated method for the treatment of patients in the acute period of myocardial infarction for the purpose of restricting the dimensions of the ischemic damage to the myocardium. | lld:pubmed |
| pubmed-article:6162997 | pubmed:language | rus | lld:pubmed |
| pubmed-article:6162997 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6162997 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6162997 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6162997 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6162997 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6162997 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6162997 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6162997 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6162997 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:6162997 | pubmed:issn | 0022-9040 | lld:pubmed |
| pubmed-article:6162997 | pubmed:author | pubmed-author:SmetnevA SAS | lld:pubmed |
| pubmed-article:6162997 | pubmed:author | pubmed-author:LazutinV KVK | lld:pubmed |
| pubmed-article:6162997 | pubmed:author | pubmed-author:SamorukovaN... | lld:pubmed |
| pubmed-article:6162997 | pubmed:author | pubmed-author:ZapevalovM... | lld:pubmed |
| pubmed-article:6162997 | pubmed:author | pubmed-author:SapryginD BDB | lld:pubmed |
| pubmed-article:6162997 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6162997 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:6162997 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6162997 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6162997 | pubmed:pagination | 21-7 | lld:pubmed |
| pubmed-article:6162997 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:6162997 | pubmed:meshHeading | pubmed-meshheading:6162997-... | lld:pubmed |
| pubmed-article:6162997 | pubmed:meshHeading | pubmed-meshheading:6162997-... | lld:pubmed |
| pubmed-article:6162997 | pubmed:meshHeading | pubmed-meshheading:6162997-... | lld:pubmed |
| pubmed-article:6162997 | pubmed:meshHeading | pubmed-meshheading:6162997-... | lld:pubmed |
| pubmed-article:6162997 | pubmed:meshHeading | pubmed-meshheading:6162997-... | lld:pubmed |
| pubmed-article:6162997 | pubmed:meshHeading | pubmed-meshheading:6162997-... | lld:pubmed |
| pubmed-article:6162997 | pubmed:meshHeading | pubmed-meshheading:6162997-... | lld:pubmed |
| pubmed-article:6162997 | pubmed:meshHeading | pubmed-meshheading:6162997-... | lld:pubmed |
| pubmed-article:6162997 | pubmed:meshHeading | pubmed-meshheading:6162997-... | lld:pubmed |
| pubmed-article:6162997 | pubmed:meshHeading | pubmed-meshheading:6162997-... | lld:pubmed |
| pubmed-article:6162997 | pubmed:meshHeading | pubmed-meshheading:6162997-... | lld:pubmed |
| pubmed-article:6162997 | pubmed:meshHeading | pubmed-meshheading:6162997-... | lld:pubmed |
| pubmed-article:6162997 | pubmed:meshHeading | pubmed-meshheading:6162997-... | lld:pubmed |
| pubmed-article:6162997 | pubmed:meshHeading | pubmed-meshheading:6162997-... | lld:pubmed |
| pubmed-article:6162997 | pubmed:meshHeading | pubmed-meshheading:6162997-... | lld:pubmed |
| pubmed-article:6162997 | pubmed:year | 1981 | lld:pubmed |
| pubmed-article:6162997 | pubmed:articleTitle | [Use of contrical with heparin in the acute period of myocardial infarct]. | lld:pubmed |
| pubmed-article:6162997 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6162997 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:6162997 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:6162997 | pubmed:publicationType | Case Reports | lld:pubmed |
